Bladder Cancer VL

A New Approach to Bladder Cancer: The ATLAS Trial's Exploration of UGN-102 and TURBT, Journal Club - Rashid Sayyid & Zachary Klaassen

Details
Rashid Sayyid and Zach Klaassen discuss the ATLAS publication focusing on the treatment of low-grade intermediate-risk, non-muscle-invasive bladder cancer using UGN-102, with or without TURBT, in a phase III trial. The trial's main objective was to evaluate the efficacy and safety of UGN-102, a mitomycin-containing reverse thermal gel, versus traditional TURBT alone. Conducted across 72 sites in t...

A Didactic Lecture on Variant Histology for Urothelial Carcinoma - Charles Guo

Details
Ashish Kamat welcomes Charles Guo to discuss variant histology in bladder urothelial carcinoma, which constitutes about 90% of all bladder cancers. Dr. Guo meticulously explains the WHO classification into noninvasive and invasive types, detailing distinguishing features, aggressive behaviors, and distinct genomic alterations of various subtypes like micropapillary, plasmacytoid, and small cell ca...

Comprehensive Geriatric Assessments in Urologic Cancer Care: Identifying Modifiable Risk Factors for Personalized Treatment - Sarah Psutka

Details
Sam Chang and Sarah Psutka discuss the importance of personalized prescriptions and rehabilitation in urologic oncology, with an emphasis on frailty evaluation and prehabilitation. Dr. Psutka urges the shift from subjective preoperative risk to objective measures for better treatment outcomes, using Comprehensive Geriatric Assessments (CGA) and anatomic assessments, while highlighting the correlat...

Device-Assisted Therapies for Bladder Cancer: History, Mechanisms, and Clinical Trials - Wei Shen Tan

Details
Ashish Kamat and Wei Shen Tan delve into a discussion on the advances in device-assisted therapies for non-muscle-invasive bladder cancer. Dr. Tan details the history, mechanisms, and clinical trials of various therapies including chemohyperthermia and electromotive drug-administrated chemotherapy (EMDA). He also highlights newer treatments such as the TAR-200 system and Jelmyto. Despite promising...

2023 BCAN Research Innovation Award - Christopher Garris

Details
Ashish Kamat interviews Chris Garris, the 2023 Bladder Cancer Research Innovation Award recipient. Dr. Garris discusses his pioneering research project aimed at overcoming immune suppressive myeloid cell barriers in bladder cancer through immune agonism. He presents the CANDI therapeutic platform which uses IL-12-inducing drug combinations to stimulate immune responses for potentially more effecti...

A Novel Mechanism of Tumor Suppression: Unveiling Transcription-Translation Conflict - Andrew Hsieh

Details
Andrew Hsieh highlights his team's research on a new tumor suppressor mechanism termed transcriptional-translational conflict. The research primarily focuses on ARID1A, a component of the SWI/SNF chromatin remodeling complex, which is frequently deregulated in bladder cancer. In absence of ARID1A, up-regulated oncogenic gene networks were observed, but no tumorigenesis occurred due to a conflict b...

Tumour Factors and the Variation in Non-Muscle Invasive Bladder Cancer Recurrence After Transurethral Resection Surgery Between Sites: Results from the RESECT Study - Kevin Gallagher

Details
Zach Klaassen and Kevin Gallagher discuss the RESECT study. RESECT, a global research initiative across five continents and over 200 hospitals, aims to improve the quality of Transurethral Resection of Bladder Tumor (TURBT) surgery and reduce early recurrence rates. Funded in 2020 and launched in late 2020-early 2021, the study utilizes social media marketing and is run on a low budget. It include...

Radical Cystectomy vs. Trimodal Therapy: Outcomes in Bladder Cancer - Alexandre Zlotta

Details
Ashish Kamat converses with Alexandre Zlotta on his study comparing radical cystectomy and trimodal therapy (TMT) for muscle-invasive bladder cancer. Dr. Zlotta highlights the evolving treatment paradigm towards organ preservation with TMT, a method combining limited resection and chemoradiation. Despite the mounting evidence for TMT, it is typically reserved for patients ineligible for surgery. D...

Extended Node Dissection in Bladder Cancer: SWOG S1011 Trial Insights - Seth Lerner

Details
Seth Lerner presents the results of a SWOG-led Phase III surgical trial (SWOG S1011) investigating the anatomic extent of node dissection during radical cystectomy for curable muscle invasive bladder cancer. The primary goal was to compare disease-free survival (DFS) in patients undergoing cystectomy, contrasting an extended node dissection with standard pelvic lymphadenectomy. After a median six...

Diversity and Excellence: The Key Criteria in BCAN's Travel Fellowship Selection Process - Max Kates & Petros Grivas

Details
Ashish Kamat welcomes Max Kates and Petros Grivas, the chair and incoming chair of the review committee for BCAN's Travel Fellowship. Dr. Grivas explains that the committee had an extremely difficult task this year due to the high-quality applications they received, which showcased talented fellows, residents, and their remarkable mentors. He also highlights the structured selection process that t...